News

Brigatinib in Patients with ALK+ NSCLC –⁠ Final Results of the J-ALTA Clinical Study

12. 9. 2022 Source: Non-Small Cell Lung Cancer

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?

Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has…

12. 9. 2022 Source: Non-Small Cell Lung Cancer

Current Findings on Progressive Fibrosis in Interstitial Lung Disease

Leading pulmonologists around the world recently published the first of a series of three review articles on interstitial lung disease in The Lancet Respiratory Medicine journal. This article focuses…

8. 9. 2022 Source: Progressive Interstitial Pulmonary Processes

Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence

Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch…

8. 9. 2022 Source: Anticoagulant Treatment

Current Treatment Options for Refractory/Relapsed CLL

How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory…

8. 9. 2022 Source: Chronic Lymphocytic Leukemia

New ESMO Recommendations for Investigating Circulating Tumor DNA

Liquid biopsy has been discussed in oncology for several decades. As we move from conference abstracts to its real-world application in clinical practice, the new recommendations of the European…

8. 9. 2022 Source: Genetic Profile and Treatment of NSCLC

Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps

The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab, omalizumab, and mepolizumab in patients with chronic rhinosinusitis and nasal polyps attempted to identify the…

7. 9. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases

A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype associated with a deterioration in quality of life and increased mortality. Early diagnosis and adequate…

7. 9. 2022 Source: Progressive Interstitial Pulmonary Processes

Limosilactobacillus reuteri as a supplement for improving periodontal health when oral hygiene is compromised

The effect of probiotics on periodontal health was investigated in a German study conducted on a group of sailors during their service at sea. Among the most common causes of the overgrowth of…

6. 9. 2022 Source: GI, colic and microbiome

Probiotics as a Helper in the Fight Against Pregnancy Gingivitis

Gingivitis is a common problem during pregnancy. In addition to quality oral hygiene, regular consumption of probiotic preparations containing certain strains of Limosilactobacillus reuteri can also…

2. 9. 2022 Source: GI, colic and microbiome

1 … 68 69 70 71 72 … 171

Back Filter by speciality

Remove filters